Notice of Annual General Meeting/Proxy Form
Released
Released
Announcement PDF
Need assistance?
Phone:
1300 850 505 (within Australia)
+61 3 9415 4000 (outside Australia)
ABN 32 056 482 403
Online:
www.investorcentre.com/contact
*L000001*
AVE
MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030
Avecho Biotechnology Limited Annual General Meeting
The Avecho Biotechnology Limited Annual General Meeting will be held on Tuesday, 27 May 2025 at 1:00pm
(AEST). You are encouraged to participate in the meeting using the following options:
MAKE YOUR VOTE COUNT
To lodge a proxy, access the Notice of Meeting and other meeting documentation visit
www.investorvote.com.au and use the below information:
Control Number: 999999
SRN/HIN: I9999999999
PIN: 99999
For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com
For your proxy appointment to be effective it must be received by 1:00pm (AEST) on Sunday,
25 May 2025.
ATTENDING THE MEETING IN PERSON
The meeting will be held at:
Grant Thornton Offices at Collins Square, Tower 5, Level 22, 727 Collins Street, Melbourne,
VIC 3008
You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form
and may elect not to receive annual reports. To do so, contact Computershare.
Samples/000001/000001
AVECHO BIOTECHNOLOGY LIMITED
ACN 056 482 403
Notice of Annual General Meeting
Explanatory Statement and Proxy Form
Date of Meeting:
Tuesday, 27 May 2025
Time of Meeting:
1.00pm (AEST)
Place of Meeting:
Grant Thornton Offices
Collins Square, Tower 5
Level 22, 727 Collins Street
Melbourne, VIC 3008
In accordance with the Corporations Act 2001 (Cth) which provides for permanent relief for companies
to use electronic communications to send meeting materials, no hard copy of the Notice of Meeting and
Explanatory Statement (AGM Materials) will be circulated, unless shareholders have elected to receive
the AGM Materials in paper form. The Notice of Meeting is also available on the Australian Securities
Exchange Announcement platform and on the Company’s website https://avecho.com.au/.
This Notice of Annual General Meeting and Explanatory Statement should be read in its entirety.
If Shareholders are in doubt as to how they should vote, they should seek advice from their accountant,
solicitor, or other professional advisor without delay.
AVECHO BIOTECHNOLOGY LIMITED
ACN 056 482 403
Registered Office: Unit A8, 2A Westall Road, Clayton, VIC 3168
NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given that the Annual General Meeting (AGM or Meeting) of shareholders of Avecho Biotechnology
Limited (the Company) will be held will be held at Grant Thornton Offices at Collins Square, Tower 5, Level 22, 727
Collins Street, Melbourne, VIC 3008 on Tuesday, 27 May 2025 at 1.00pm (AEST).
AGENDA
The Explanatory Statement and Proxy Form which accompany, and form part of, this Notice include defined terms
and describe in more detail the matters to be considered. Please consider this Notice, the Explanatory Statement,
and the Proxy Form in their entirety. Terms and abbreviations used in this Notice and Explanatory Statement are
defined in the Glossary.
ORDINARY BUSINESS
Receipt and Consideration of Financial Statements and Reports
To receive and consider the Annual Report of the Company for the financial year ended 31 December 2024, which
includes the Financial Report, the Directors' Report, and the Auditor's Report.
There is no requirement for shareholders to approve these reports. Accordingly, no resolution will be put to
shareholders on this item of business.
Resolution 1: Adoption of Remuneration Report
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That for the purpose of Section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report
(included in the Directors' Report) for the financial year ended 31 December 2024 be adopted.”
Resolution 2: Re-Election of Dr Gregory Collier as a Director of the Company
To consider, and if thought fit, pass the following resolution as an ordinary resolution:
“That, for the purposes of clause 20.1 of the Constitution, Listing Rule 14.4, and for all other purposes, Dr Gregory
Collier, who retires by rotation in accordance with the Constitution, and who, being eligible, offers himself for reelection, be re-elected as a Director of the Company.”
Resolution 3: Approval to grant Options to Directors (or their nominees)
To consider, and if thought fit, pass each of the following resolutions as ordinary resolutions:
Resolution 3(a): Options to Dr Gregory Collier (or his nominee)
“That, pursuant to and in accordance with ASX Listing Rule 10.14, and for all other purposes, approval be given to
issue under the Company’s Equity Incentive Plan a total of 6,338,595 unlisted options to Dr Gregory Collier (a Director
of the Company), or his nominee, expiring 42 months from the date of issue, and having the exercise price, vesting
date and other terms and conditions set out or described in the Explanatory Statement which accompanied and
formed part of the Notice of the Meeting.”
-2-
Resolution 3(b): Options to Dr Ross Murdoch (or his nominee)
“That, pursuant to and in accordance with ASX Listing Rule 10.14, and for all other purposes, approval be given to
issue under the Company’s Equity Incentive Plan a total of 3,169,298 unlisted options to Dr Ross Murdoch (a Director
of the Company), or his nominee, expiring 42 months from the date of issue, and having the exercise price, vesting
date and other terms and conditions set out or described in the Explanatory Statement which accompanied and
formed part of the Notice of the Meeting.”
Resolution 3(c): Options to Mr Matthew McNamara (or his nominee)
“That, pursuant to and in accordance with ASX Listing Rule 10.14, and for all other purposes, approval be given to
issue under the Company’s Equity Incentive Plan a total of 3,169,298 unlisted options to Mr Matthew McNamara (a
Director of the Company), or his nominee, expiring 42 months from the date of issue, and having the exercise price,
vesting date and other terms and conditions set out or described in the Explanatory Statement which accompanied
and formed part of the Notice of the Meeting.”
Resolution 3(d): Options to Ms Katherine Connell (or her nominee)
“That, pursuant to and in accordance with ASX Listing Rule 10.14, and for all other purposes, approval be given to
issue under the Company’s Equity Incentive Plan a total of 3,169,298 unlisted options to Ms Katherine Connell (a
Director of the Company), or her nominee, expiring 42 months from the date of issue, and having the exercise price,
vesting date and other terms and conditions set out or described in the Explanatory Statement which accompanied
and formed part of the Notice of the Meeting.”
SPECIAL BUSINESS
Resolution 4: Approval of 10% Placement Facility
To consider and, if thought fit, to pass the following as a special resolution:
“That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the
issue of Equity Securities up to 10% of the fully paid ordinary issued capital of the Company (at the time of the issue)
calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the
Explanatory Statement.”
BY ORDER OF THE BOARD
Melanie Leydin
Company Secretary
24 April 2025
-3-
NOTES
Notes
1.
Entire Notice: The details of the resolutions contained in the Explanatory Statement accompanying this Notice of Meeting
should be read together with, and form part of, this Notice of Meeting.
2.
Record Date: The Company has determined that for the purposes of the Annual General Meeting, only those persons who
are registered as Shareholders at 7.00pm (AEST) on the date 48 hours before the date of the Meeting. Only those persons
will be entitled to vote at the Meeting and transfers registered after that time will be disregarded in determining entitlements
to attend and vote at the Meeting.
3.
Proxies
a.
Votes at the Meeting may be given personally or by proxy, attorney or representative.
b.
Each shareholder has a right to appoint one or two proxies. A proxy need not be a shareholder of the Company.
c.
Where a shareholder is entitled to cast two or more votes, the shareholder may appoint two proxies and may specify
the proportion or the number of votes each proxy is appointed to exercise.
d.
If a shareholder appoints two proxies, and the appointment does not specify the proportion or the number of the
shareholder’s votes, each proxy may exercise half of the votes. If a shareholder appoints two proxies, neither proxy
may vote on a show of hands.
e.
A proxy must be signed by the shareholder or their attorney who has not received any notice of revocation of the
authority. Proxies given by corporations must be signed in accordance with corporation’s constitution and Corporations
Act.
f.
To be effective, proxy forms must be received by the Company’s share registry (Computershare Investor Services Pty
Limited) no later than 48 hours before the commencement of the Meeting, this is no later than 1.00pm (AEST) on
Sunday, 25 May 2025. Any proxy received after that time will not be valid for the scheduled Meeting.
4.
Corporate Representative
Any corporate shareholder who has appointed a person to act as its corporate representative at the Meeting should provide
that person with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that
company’s representative. The authority may be sent to the Company and/or registry in advance of the Meeting or handed
in at the Meeting when registering as a corporate representative.
5.
Voting Exclusion Statement
Resolution 1
In accordance with sections 250R(4) and 250BD(1) of the Corporations Act, a vote must not be cast (in any capacity,
including as a proxy), and the Company will disregard any votes purported to be cast, on this Resolution by, or on behalf of,
a member of the Key Management Personnel (KMP), details of whose remuneration are included in the remuneration report,
or a Closely Related Party of such a member (either being a KMP voter), unless the KMP voter is casting a vote on behalf
of a person who is not a KMP voter (including as a proxy) and either:
a. the KMP voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the resolution; or
b. the KMP voter is the Chair of the Meeting and the appointment of the Chair as proxy:
(i) does not specify the way the proxy is to vote on the Resolution; and
(ii) expressly authorises the Chair of the Meeting to exercise the proxy even if the Resolution is connected directly or
indirectly with the remuneration of a member of the KMP for the Company or the consolidated entity.
If you appoint the Chair of the Meeting as your proxy and you do not direct the Chair of the Meeting on how to vote, you will
be expressly authorising the Chair of the Meeting to exercise the proxy even if the relevant Resolution is connected directly
or indirectly with the remuneration of a member of the KMP for the Company.
If the Chair of the Meeting is appointed as a proxy for a person who is permitted to vote on this Resolution, the Chair of the
Meeting will vote any proxies which do not indicate on their proxy form the way the Chair of the Meeting must vote in favour
of this Resolution. In exceptional circumstances, the Chair of the Meeting may change their voting intention on the
Resolution, in which case an ASX announcement will be made. Shareholders may also choose to direct the Chair of the
Meeting to vote against the Resolution or to abstain from voting.
If you purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as indicated
above) and you may be liable for breaching the voting restrictions that apply to you under the Corporations Act.
Resolution 2
There are no voting exclusions on this Resolution.
-4-
Resolutions 3(a) to 3(d)
The Company will disregard any votes cast in favour of each of Resolutions 3(a), 3(b), 3(c), and 3(d) (respectively and
separately) by or on behalf of:
(a) a person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the Company’s Equity
Incentive Plan, being the following directors:
a.
b.
c.
d.
Dr Gregory Collier (or his nominee);
Dr Ross Murdoch (or his nominee);
Mr Matthew McNamara (or his nominee); and
Ms Katherine Connell (or her nominee); or
(b) an associate of those persons.
However, this does not apply to a vote cast in favour of any of these Resolutions by:
(a)
(b)
(c)
a person as a proxy or attorney for a person who is entitled to vote on the Resolution(s), in accordance with directions
given to the proxy or attorney to vote on the Resolution(s) in that way; or
the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the Resolution(s), in accordance
with a direction given to the Chair to vote on the Resolution(s) as the Chair decides; or
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met:
a. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is
not an associate of a person excluded from voting, on the Resolution(s); and
b. the holder votes on the Resolution(s) in accordance with directions given by the beneficiary to the holder to vote
in that way.
A further restriction also applies to KMP and their closely related parties voting undirected proxies on these Resolutions see item 6 below.
Resolution 4
As at the date of despatch of this Notice, the Company is not proposing to make an issue of Equity Securities under Listing
Rule 7.1A.2 and, therefore, a voting exclusion statement is not required by Listing Rule 7.3A.7.
However, if, between the date of despatch of this Notice and the date of the Meeting, the Company proposes to make an
issue of Equity Securities under Listing Rule 7.1A.2, the Company will disregard votes cast in favour of this Resolution by or
on behalf of:
a. any person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue
(except a benefit solely by reason of being a holder or ordinary securities in the Company); or
b. an associate of that person or those persons.
However, this does not apply to a vote cast in favour of the Resolution by:
a. a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given
to the proxy or attorney to vote on the Resolution in that way; or
b. the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with
a direction given to the Chair of the Meeting to vote on the Resolution as the Chair of the Meeting decides; or
c. a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met:
(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is
not an associate of a person excluded from voting; and
(ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in
that way.
6.
Restrictions on KMPs voting undirected proxies:
A vote must not be cast as proxy on Resolution 1 or any of Resolutions 3(a) to 3(d) by a member of the KMP (as defined by
the Corporations Act) or a closely related party of KMP.
However, a person described above (a Restricted Voter) may cast a vote on behalf of a person who is not a Restricted
Voter on any of Resolution 1 or Resolutions 3(a) to 3(d) as a proxy if:
(a) The Restricted Voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution(s);
or
(b) The Chair of the Meeting is the Restricted Voter and the written appointment of the Chair as proxy does not specify the
way the proxy is to vote on the Resolution(s) and expressly authorises the Chair to exercise the proxy even though the
Resolution(s) is or are connected directly or indirectly with the remuneration of a member of the KMP.
-5-
If you appoint the Chair of the Meeting as your proxy and you do not direct the Chair how to vote, you will be expressly
authorising the Chair of the Meeting to exercise the proxy even if the relevant Resolution is connected directly or indirectly
with the remuneration of a member of the KMP for the Company.
7.
Enquiries
Shareholders are invited to contact the Company Secretary, Melanie Leydin on 1300 384 692 if they have any queries in
respect of the matters set out in these documents.
-6-
EXPLANATORY STATEMENT
ORDINARY BUSINESS
Receipt and Consideration of Financial Statements and Reports
A copy of the Annual Report for the financial year ended 31 December 2024 (which incorporates the Company's
Financial Report, Directors Report (including the Remuneration Report) and the Auditors Report) is available on
the Company's website at http://avecho.com.au/ or via the Company's announcement platform on ASX.
Alternatively, you may obtain a copy free of charge in hard copy form by contacting the Company by phone at
1300 384 692, and you may request that this occurs on a standing basis for future years. There is no requirement
for Shareholders to approve the Annual Report.
Shareholders will be given reasonable opportunity at the Meeting to ask questions and make comments on the
Financial Report, the Directors’ Report, and the Auditor’s Report. Questions for the Company’s auditors relating
to the conduct of the audit, preparation and contents of the audit report, accounting policies adopted by the
Company in relation to the preparation of its financial statements, and the independence of the auditors in relation
to the conduct of the audit, must be submitted no later than 5 business days before the Meeting to the Company
Secretary at the Company's registered office.
Resolution 1: Adoption of Remuneration Report
Background
Section 250R(2) of the Corporations Act requires that a resolution to adopt the Remuneration Report must be put
to the vote at the Annual General Meeting. The vote on this Resolution is advisory only and does not bind the
Directors or the Company.
The Remuneration Report is set out in the Directors’ Report in the Company’s Annual Report. The Remuneration
Report sets out the Company’s remuneration arrangements for the Directors and senior management of the
Company.
In accordance with Section 250SA of the Corporations Act 2001, Shareholders will be provided with a reasonable
opportunity to ask questions concerning, or make comments on, the remuneration report at the AGM.
In accordance with Division 9 of Part 2G.2 of the Corporations Act, if twenty five (25%) per cent or more of votes
that are cast are voted against the adoption of the Remuneration Report at two consecutive Annual General
Meetings, Shareholders will be required to vote at the second of those Annual General Meetings on a resolution
(a Spill Resolution) that another meeting be held within 90 days at which all of the Company’s Directors (other
than the Managing Director) must go up for re-election.
At the Company’s last AGM, the votes cast against the Remuneration Report were less than twenty-five (25%)
per cent of the total votes cast on that resolution and, accordingly, a Spill Resolution will not, under any
circumstances, be required for this Meeting.
Voting Exclusions
For voting exclusions refer to Note 5.
Board Recommendation
Noting that each Director has a personal interest in their own remuneration from the Company (as such interests
are described in the Remuneration Report) and, as described in the voting exclusions on this Resolution (set out
in the Notice of AGM), that each Director (or any Closely Related Party of a Director) is excluded from voting their
shares on this Resolution, the Board encourages all eligible shareholders to cast their votes in favour of this
Resolution.
-7-
Voting Intention
The Chair of the Meeting intends to vote all available undirected proxies in favour of this Resolution.
Resolution 2: Re-Election of Dr Gregory Collier as a Director of the Company
Background
The Constitution of the Company (clauses 20.1(a) and 20.6) and Listing Rule 14.4 require that at least one Director
(excluding the Managing Director) must stand for re-election at each Annual General Meeting. Dr Collier is now
retiring in accordance with these requirements and, being eligible, offers himself for re-election.
Dr Collier, Chair of the Board, has been appointed as a Director of the Company on 13 April 2015 and has held
the position of Executive Chair between 27 March 2019 and 1 May 2020.
Dr Collier has more than 25 years’ experience spanning operational, clinical, and scientific aspects of
pharmaceutical research, development, and commercialisation. He has led the planning and execution of multiple
commercial transactions including in and out licensing deals and major M&A activities, and he has successfully
taken a drug from discovery through to regulatory approval.
Notably, Dr Collier steered ChemGenex Pharmaceuticals Limited from a research-based company with a market
capitalisation of $10 million to a company with completed clinical trials and regulatory dossiers submitted to the
FDA and EMA. In 2011, ChemGenex was sold to Cephalon Inc. (now subsidiary of Teva Pharmaceuticals
Industries Limited) for $230 million.
In addition, Dr Collier has worked with several public and private biotechnology companies on matters ranging
from strategy and commercialisation through to partnering and capital raising. Including a US drug development
company to raise capital and expand shareholder base with institutional investors, pre-product private biotech
company to raise capital, refocus operations and deliver M&A opportunities. Dr Collier worked with and
established a USA based microbiome start-up to raise capital, develop strategic plan, develop regulatory and
commercialisation strategies and successfully complete a clinical trial.
Prior to his commercial pharmaceutical career, Dr Collier had an outstanding academic career resulting in over
150 peer reviewed publications, and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin
Professor at Deakin University and also held positions at Melbourne University, Monash University and the
University of Toronto. In 2010, Dr Collier was awarded the Roche Award of Excellence.
Voting Exclusions
There are no voting exclusions on this Resolution.
Board Recommendation
The Board (with Dr Gregory Collier abstaining in his capacity as Director of the Company) recommends that
shareholders vote in favour of the re-election of Dr Gregory Collier as it considers that his qualifications,
experience, skills, and expertise are appropriate for the Board position and will enable him to act in the best
interests of the Company and its shareholders. The Board also considers Dr Collier as an independent Director
of the Company.
Voting Intention
The Chair of the Meeting intends to vote all undirected proxies in favour of the Resolution.
-8-
Resolution 3: Approval to grant Options to Directors (or their nominees)
Background
Resolutions 3(a) to 3(d) provide for a total of up to 15,846,489 unlisted options (Options) being granted under
the Company’s Equity Incentive Plan (Plan), previously approved by shareholders on 23 May 2023, to the four
Non-Executive Directors of the Company (or their respective nominees) as described below:
Director (or nominee)
Number of
Options
6,338,595
3,169,298
3,169,298
3,169,298
15,846,489
Dr Gregory Collier
Dr Ross Murdoch
Mr Matthew McNamara
Mr Katherine Connell
Total
The Options’ exercise price will be at a 45% premium to a 30-day VWAP prior to the grant date and will expire 42
months from the date of issue. The Options will vest in four tranches, as detailed below:
a)
b)
c)
d)
Tranche 1: 25% of the Options to vest immediately upon issue (Date of Issue);
Tranche 2: 25% of the Options to vest 12 months from Date of Issue;
Tranche 3: 25% of the Options to vest 24 months from Date of Issue; and
Tranche 4: 25% of the Options to vest 36 months from Date of Issue.
The Options will vest subject to service conditions being met on the vesting date unless a change in employment
terms has been agreed in writing with the Company regarding the treatment of unvested Options where they
cease to be Directors prior to the vesting date.
A summary of the material terms of the Options and Equity Incentive Plan are respectively set out in Annexures
A and B, respectively.
Directors’ Remuneration Packages and Interests
As at the date of this Notice, the details (including the amount) of the current total remuneration package of each
of the Directors to whom (or to whose nominees) Options would be issued if Resolutions 3(a) to 3(d) are passed
are:
Director (or nominee)
Dr Gregory Collier
Dr Ross Murdoch
Mr Matthew McNamara
Ms Katherine Connell
Remuneration Package Details (excluding the proposed Options)
A$100,000 per annum
A$55,275 per annum
A$55,275 per annum
A$55,275 per annum
Management has prepared an assessment of the indicative fair value of the Options as summarised below. The
value is indicative only, based on assumptions relevant at the date of the calculation, being 31 March 2025.
Different assumptions may be relevant at Date of Issue which may alter the value of the Options for financial
reporting purposes. The total remuneration packages in the above table would be increased for each of the above
Directors by the total per Director set out in the following table, based on the assumptions. The actual valuation
amount will not be able to be calculated until the Options are issued, when the exercise price will be known (at
which time other assumptions may also have changed).
Assessment:
Indicative fair value per Option
Number of Options per Director (except for Dr Gregory Collier)
Number of Options for Dr Gregory Collier
Total $ per Director (except for Dr Gregory Collier)
Total $ for Dr Gregory Collier
Total Options
Total $
-9-
$0.006499
3,169,298
6,338,595
$20,597
$41,195
15,846,489
$102,986
The indicative fair value was calculated using the Binomial valuation model. The assumptions used in the valuation
model were as follows:
Assumptions:
Valuation Date
Spot price
Exercise Price
Expiry Date
Risk Free Rate
Volatility
31 March 2025
$0.00670
$0.00972*
42 months from Date of Issue
3.79%
237.21%
*Based on 45% premium of a 30-day VWAP immediately prior to 31 March 2025.
As at the date of this Notice, the Directors who are proposed to receive the Options have the following direct and
indirect interests in shares and/or options of the Company:
Director/Shareholder
(and/or associates)
Dr Gregory Collier
Dr Ross Murdoch
Mr Matthew McNamara
Ms Katherine Connell
Existing Shares
Existing quoted options^
Existing unquoted options#
9,833,333 (0.31%)
3,333,333 (0.11%)
1,666,666 (0.05%)
Nil
11,749,999
2,499,999
2,499,999
Nil
Nil
Nil
Nil
3,993,644
^Quoted options exercisable at $0.012 each, expiring on 10 May 2026.
#Unquoted options exercisable at $0.0056 each, expiring on 26 October 2027.
Following issue of the Options, each of the Directors in the above table (or their respective nominees) would hold
the following securities in the Company:
Director/Shareholder
(and/or associates)
Dr Gregory Collier
Dr Ross Murdoch
Mr Matthew McNamara
Ms Katherine Connell
Existing Shares
Total options
Holding if options exercised+
9,833,333 (0.31%)
3,333,333 (0.11%)
1,666,666 (0.05%)
Nil
18,088,594
5,669,297
5,669,297
7,162,942
27,921,927 (0.87%)
9,002,630 (0.28%)
7,335,963 (0.23%)
7,162,942 (0.22%)
+
On the assumptions that Directors will exercise all their Options and that the issued capital of 3,173,463,679 Shares is diluted by the same number
of Options (i.e.,36,590,130 Options) exercised by the Directors.
Corporations Act
The Board has formed the view that the issues of Options to the above Directors (or their respective nominees)
do not require Shareholder approval under section 208 of the Corporations Act as the issues constitute
“reasonable remuneration” in accordance with section 211 of the Corporations Act.
A “financial benefit” is defined in section 229 of the Corporations Act and includes granting an option to a related
party.
Section 228 of the Corporations Act defines a “related party” for the purposes of Chapter 2E to include:
directors of the public company (section 228(2)(a)); and
an entity controlled by directors of the public company (section 228(4)). Section 228(5) provides that an entity
is a related party of a public company at a particular time if the entity was a related party of the public company
of a kind referred to in subsection (1), (2), (3) or (4) at any time within the previous 6 months.
In reaching this view, the Board considers the proposed grant of Options aligns the interests of each of the above
Directors with the interests of Shareholders. The grant of Options to each of the above Directors is a cost-effective
form of remuneration when compared to the payment of cash consideration.
Consistent with the desire to minimise cash expenditures, the Board believes that having regard to the Company's
current cash position, and the Company’s objective to use available cash to fund its operations in the near future,
and in order to compensate the above Directors in line with current market practices, Options provide an
- 10 -
appropriate and meaningful remuneration component to the above Directors that is aligned with Shareholder
interests.
If Resolutions 3(a) to 3(d) are passed and the Options are issued, each of the Directors proposed to receive
Options under these Resolutions (including direct and indirect interests) will have a relevant interest in the
Compan
Share your feedback
Discover